News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Pfizer Inc.'s Crizotinib Wipes Out Rare Lymphoma in Two Test Cases
February 24, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Bloomberg -- Pfizer Inc.’s experimental drug to treat a type of lung cancer appeared to wipe out a rare form of lymphoma in two severely ill patients in test cases reported by doctors.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Pfizer
MORE ON THIS TOPIC
Rare diseases
Regeneron Eyes 2026 Filing for siRNA Myasthenia Gravis Drug After Phase III Win
August 27, 2025
·
2 min read
·
Tristan Manalac
Podcast
Lilly’s Obesity Pill Heads to the FDA, AbbVie Bets on Psychedelics, HHS Unveils More Change
August 27, 2025
·
1 min read
·
Jef Akst
Obesity
Lilly Plots Path to FDA After Second Phase III Readout for Orforglipron
August 26, 2025
·
2 min read
·
Tristan Manalac
Rare diseases
Argenx Eyes ‘Broadest Label’ for Vyvgart in Myasthenia Gravis After Positive Phase III Data
August 26, 2025
·
2 min read
·
Tristan Manalac
